SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Hagen Chris)
 

Search: WFRF:(Hagen Chris) > Long-term patient s...

  • Flossmann, Oliver (author)

Long-term patient survival in ANCA-associated vasculitis

  • Article/chapterEnglish2011

Publisher, publication year, extent ...

  • 2010-11-24
  • BMJ,2011

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:3fa26551-91f8-417d-8cf6-99c30beb11e4
  • https://lup.lub.lu.se/record/1876627URI
  • https://doi.org/10.1136/ard.2010.137778DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Background Wegener's granulomatosis and microscopic polyangiitis are antineutrophil cytoplasm antibodies (ANCA)-associated vasculitides with significant morbidity and mortality. The long-term survival of patients with ANCA associated vasculitis treated with current regimens is uncertain. Objective To describe the long-term patient survival and possible prognostic factors at presentation in an international, multicentre, prospectively recruited representative patient cohort who were treated according to strictly defined protocols at presentation and included the full spectrum of ANCA-associated vasculitis disease. Methods Outcome data were collected for 535 patients who had been recruited at the time of diagnosis to four randomised controlled trials between 1995 and 2002. Trial eligibility was defined by disease severity and extent, covered the spectrum of severity of ANCA-associated vasculitis and used consistent diagnostic criteria. Demographic, clinical and laboratory parameters at trial entry were tested as potential prognostic factors in multivariable models. Results The median duration of follow-up was 5.2 years and 133 (25%) deaths were recorded. Compared with an age-and sex-matched general population there was a mortality ratio of 2.6 (95% CI 2.2 to 3.1). Main causes of death within the first year were infection (48%) and active vasculitis (19%). After the first year the major causes of death were cardiovascular disease (26%), malignancy (22%) and infection (20%). Multivariable analysis showed an estimated glomerular filtration rate <15 ml/min, advancing age, higher Birmingham Vasculitis Activity Score, lower haemoglobin and higher white cell count were significant negative prognostic factors for patient survival. Conclusion Patients with ANCA-associated vasculitis treated with conventional regimens are at increased risk of death compared with an age-and sex-matched population.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Berden, Annelies (author)
  • de Groot, Kirsten (author)
  • Hagen, Chris (author)
  • Harper, Lorraine (author)
  • Heijl, CarolineLund University,Lunds universitet,Njurmedicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Nephrology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-clh (author)
  • Höglund, PeterLund University,Lunds universitet,Avdelningen för klinisk kemi och farmakologi,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Clinical Chemistry and Pharmacology,Department of Laboratory Medicine,Faculty of Medicine(Swepub:lu)kfar-pho (author)
  • Jayne, David (author)
  • Luqmani, Raashid (author)
  • Mahr, Alfred (author)
  • Mukhtyar, Chetan (author)
  • Pusey, Charles (author)
  • Rasmussen, Niels (author)
  • Stegeman, Coen (author)
  • Walsh, Michael (author)
  • Westman, KerstinLund University,Lunds universitet,Njurmedicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Nephrology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)njur-kwe (author)
  • NjurmedicinSektion II (creator_code:org_t)

Related titles

  • In:Annals of the Rheumatic Diseases: BMJ70:3, s. 488-4941468-20600003-4967

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view